ThinkRadial: A Prospective Study of Transradial deTACE in HCC Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

38 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-08-21

Study Completion Date

2025-08-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a prospective, observational clinical trial designed to evaluate the feasibility, safety, and effectiveness of performing transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) using a transradial arterial approach. Traditionally, TACE procedures are performed through the femoral artery in the groin, but using the radial artery in the wrist may reduce complications, improve patient comfort, and allow for faster recovery.

In this study, eligible patients with unresectable HCC who meet the inclusion criteria-such as preserved liver function (Child-Pugh A), good performance status, and tumors of a certain size and number-will undergo TACE using HepaSphere drug-eluting embolic materials via radial access. No randomization or drug intervention will be assigned by protocol, as the treatment will follow standard clinical practice.

The study will follow participants for 12 months to assess technical success, tumor response using imaging criteria (mRECIST), safety outcomes including adverse events, and overall survival. The study is being conducted at Asan Medical Center in Seoul, Korea, and has received Institutional Review Board approval.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Study to Evaluate Safety of Deb-TACE With 100µ Beads in Patients With Non Resectable HCC

NCT02670122

Hepatocellular Carcinoma

COMPLETED

Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients

NCT02956772

Primary Hepatocellular Carcinoma

UNKNOWN PHASE2

Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma

NCT06911255

Hepatocellular Carcinoma (HCC) Unresectable Hepatocellular Carcinoma

RECRUITING PHASE1/PHASE2

DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC

NCT04967482

Hepatocellular Carcinoma Non-resectable

UNKNOWN NA

Drug-eluting Bead in Hepatocellular Carcinoma

NCT01332669

Hepatocellular Carcinoma

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective observational study to evaluate the feasibility, safety, and tumor response of transarterial chemoembolization (TACE) using a transradial approach in patients with hepatocellular carcinoma (HCC). Eligible patients will undergo drug-eluting beads TACE via radial access and be followed for up to 12 months. The primary outcome is the technical success rate of the procedure. Secondary outcomes include survival rate, tumor response by mRECIST, and adverse events.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Transradial drug-eluting beadsTransarterial Chemoembolization (DEB-TACE) group

Patients with hepatocellular carcinoma (HCC) who undergo transarterial chemoembolization (TACE) using a transradial arterial approach with HepaSphere microspheres. Participants will be observed prospectively to evaluate the technical success, safety, and tumor response following treatment.

Transradial drug-eluting beadsTransarterial Chemoembolization (DEB-TACE)

Intervention Type PROCEDURE

Transarterial chemoembolization performed through the radial artery using HepaSphere drug-eluting microspheres in patients with hepatocellular carcinoma.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transradial drug-eluting beadsTransarterial Chemoembolization (DEB-TACE)

Transarterial chemoembolization performed through the radial artery using HepaSphere drug-eluting microspheres in patients with hepatocellular carcinoma.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

* Age between 19 and 80 years
* Diagnosed with hepatocellular carcinoma (HCC)
* Child-Pugh class A
* ECOG performance status 0 or 1
* Tumor size between 3 and 10 cm, with 1 to 7 nodules
* Ability to provide written informed consent

Exclusion Criteria

* Child-Pugh class B or C
* Presence of other malignancies
* CKD stage 4 or 5 (eGFR \< 30 mL/min/1.73m²)
* Known allergy or contraindication to contrast media
* Pregnancy or breastfeeding

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No